Halozyme share price logo

Halozyme

NASDAQ: HALO

Large Cap

$107.68

+0.29

(+0.27%)

Live

as on

Halozyme Stock Performance

as on September 11, 2026 at 2:14 am IST

  • Day's Low

    Day's High

    $106.36
    $107.84
    downward going graph

    1.23%

    Downside

    0.15%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $61.23
    $111.15
    downward going graph

    43.14%

    Downside

    3.22%

    Upside

    downward going graph

Halozyme share price movements today

Previous Close
$107.39
Open
$106.71
Volume
129.4K
Market Cap
$12.3B
Day's Low - High
$106.36 - $107.84
52 Week Low - High
$61.23 - $111.15

Halozyme Historical Returns

1 Month Return
+ 4.65 %
3 Month Return
+ 52.33 %
1 Year Return
+ 41.68 %
3 Year Return
+ 178.86 %
5 Year Return
+ 160.4 %

Halozyme Stock Fundamentals & Key Indicators

Check Halozyme market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$12.3B

EPS (TTM)

8.5769

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.43%

PE Ratio (TTM)

31.86

Industry PE ratio

10.26

PEG Ratio

-2.5

EBITDA

1.1B

Revenue (TTM)

1.7B

Profit Margin

24.86%

Return On Equity TTM

173.67%

Halozyme Stock Valuation

Track how Halozyme P/E has moved over time to understand its valuation trends.

Halozyme in the last 5 years

  • Overview

  • Trends

Lowest (10.98x)

June 30, 2025

Industry (10.26x)

September 10, 2026

Today (31.86x)

September 10, 2026

Highest (23.06x)

December 31, 2022

LowHigh

Today’s Price to Earnings Ratio: 31.86x

Halozyme vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Halozyme with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$12.3B160.4%31.8624.86%NA
BUY$44.6B614.61%NA0.00%NA
BUY$138.4B181.2%30.5486.04%NA
BUY$56.0B-69.82%-16.99-12.57%NA
BUY$85.2B24.16%19.2884.86%45.660000000000004%

Stock Returns calculator for Halozyme Stock including INR - Dollar returns

The Halozyme stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Halozyme investment value today

Current value as on today

₹1,53,959

Returns

₹53,959

(+53.96%)

Returns from Halozyme Stock

₹42,058 (+42.06%)

Dollar Impact

₹11,901 (+11.9%)

Analyst Recommendation on Halozyme Stock

Based on 7 analysts

BUY

71.43%

Buy

14.29%

Hold

14.29%

Sell

Based on 7 analysts, 71.42857142857143% of analysts recommend a 'BUY' rating for Halozyme. Average target price of $99.56

Halozyme Share Price Target

Get share price movements and forecasts by analysts on Halozyme.

What analysts predicted

-8.16%DOWNSIDE

Target Price

$99.56

Current Price

$107.68

Analyzed by

7 Analysts

Target

$99.56

Halozyme target price $99.56, a slight downside of -8.16% compared to current price of $107.68. According to 7 analysts rating.

Indian Investors' Interest in Halozyme Stock

Search interest for Halozyme Stock has increased by 83% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:83% versus previous 30 day period

Halozyme Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
195
231
290
298
264
325
354
451
376
480
Gross Profit
149
173
240
255
198
261
281
349
267
401
Operating Income
95
117
163
175
141
202
217
254
184
287
EBITDA
120
142
190
203
168
229
243
-69
219
320
Interest Expense
4
4
4
4
4
4
4
4
5
5
Depreciation
20
20
20
20
20
20
20
26
33
33
Income Before Tax
96
117
165
178
143
204
218
-100
180
284
Income Tax Expense
19
24
28
41
25
39
43
40
30
54
Net Income
76
93
137
137
118
165
175
-141
150
229
Net Profit Margin
39.22%
40.30%
47.23%
45.98%
44.59%
50.71%
49.46%
-31.34%
39.83%
47.80%

Halozyme Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
146
316
151
195
267
443
660
829
1,015
1,396
Gross Profit
113
285
141
150
224
361
520
636
855
1,091
Operating Income
-83
81
-69
-67
144
275
267
337
551
816
EBITDA
-80
83
-66
-63
147
278
315
451
656
573
Interest Expense
19
21
18
11
20
7
16
18
18
18
Depreciation
-
2
2
4
3
2
49
84
81
88
Income Before Tax
-101
61
-79
-72
129
248
248
348
557
466
Income Tax Expense
1
-1
0
0
0
-154
46
66
113
149
Net Income
-103
62
-80
-72
129
402
202
281
444
316
Net Profit Margin
-70.23%
19.89%
-52.90%
-36.86%
48.24%
90.84%
30.62%
33.96%
43.74%
22.69%

Halozyme Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
93
137
137
118
165
175
-141
150
229
Operating Cash Flow
55
115
178
154
99
178
219
180
240
Investing Cash Flow
-42
-167
29
-90
84
201
-741
-2
-62
Financing Cash Flow
9
18
-246
-3
-298
-22
239
-1
-326
Change in Cash
23
-33
-38
60
-114
357
-285
175
-148

Halozyme Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
62
-80
-72
129
402
202
281
444
316
Operating Cash Flow
134
-49
-85
55
299
240
388
479
651
Investing Cash Flow
-163
2
-5
78
-406
-487
-96
-262
-545
Financing Cash Flow
131
-63
153
-106
77
362
-407
-218
-85
Change in Cash
101
-110
62
27
-28
115
-116
-2
20

Mutual Funds that own Halozyme Stock

Check out the Mutual Funds with significant holdings in Halozyme.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
8.189546%
9294972
Delaware Group Equity Funds V
2.824687%
3205964
John Hancock Funds III
1.257656%
1427415
Fidelity Concord Street Trust
1.042295%
1182985
T. ROWE PRICE QUANTITATIVE MANAGEMENT FUNDS, INC.
1.035524%
1175300

Global Institutional Holdings in Halozyme

Funds
Holdings
iShares
11.56%
Vanguard
9.15%
SPDR
3.26%
First Trust
1.59%
Schwab
0.98%

Halozyme News & Key Events

  • img

    Today's Timeline - 02 September

    Wed, 06:00 PM

    -

    Halozyme to participate in three investor conferences in September 2026, featuring discussions with executives.

    Wed, 10:10 PM

    -

    H.C. Wainwright maintains Buy rating on Halozyme, citing Novartis deal as a potential challenge but sees future growth.

Insights on Halozyme

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 376.70M → 480.99M (in $), with an average increase of 21.7% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, HALO stock has moved up by 52.3%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, HALO has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -141.59M → 229.91M (in $), with an average increase of 114.6% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 457.8% return, outperforming this stock by 416.1%

About Halozyme

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
OrganisationHalozyme
Headquarters12390 El Camino Real, San Diego, CA, United States, 92130
IndustryBiotechnology
CEODr. Helen I. Torley M.B. Ch. B., M.R.C.P.
E-voting on sharesClick here to vote

Key Management of Halozyme

Name

Title

Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.

President, CEO & Director

Mr. Mark Snyder Esq.

Executive VP, General Counsel, Chief Compliance Officer & Corporate Secretary

Mr. Rhys de Callier

Chief Strategy Officer

Mr. Chase Coffman Ph.D.

President of Hypercon

Mr. Paul Spence

Chief Commercial Officer

Mr. Darren Snellgrove

Senior VP & CFO

Mr. Brian Sweeney

Chief Human Resources Officer

Mr. David A. Ramsay MBA

President of Drug Delivery

Dr. Christopher Wahl M.B.A., M.D.

Chief Scientific Officer

Dr. Charles P. Theuer M.D., Ph.D.

Chief Medical Officer

FAQs

What is Halozyme share price today?

Halozyme share price today is $107.68 as on . Halozyme share today touched a day high of $107.84 and a low of $106.36.

What is the 52 week high and 52 week low for Halozyme share?

Halozyme share touched a 52 week high of $111.15 on and a 52 week low of $61.23 on . Halozyme stock price today i.e. is trending at $107.68,which is 3.12% down from its 52 week high and 75.88% up from its 52 week low.

What is Halozyme's market capitalisation today?

Halozyme market capitalisation is $0.01T as on .

How to invest in Halozyme Stock (HALO) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Halozyme on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Halozyme Shares that will get you 0.0139 shares as per Halozyme share price of $107.68 per share as on September 10, 2026 at 8:44 pm IST.

What is the minimum amount required to buy Halozyme Stock (HALO) from India?

Indian investors can start investing in Halozyme (HALO) shares with as little as ₹95.43 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹954.30 in Halozyme stock (as per the Rupee-Dollar exchange rate as on ). Based on Halozyme share’s latest price of $107.68 as on September 10, 2026 at 8:44 pm IST, you will get 0.0929 shares of Halozyme. Learn more about fractional shares .

What are the returns that Halozyme has given to Indian investors in the last 5 years?

Halozyme stock has given 160.4% share price returns and 28.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?